Your browser doesn't support javascript.
loading
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin, Shannon N; Fu, Siqing; Tsimberidou, Apostolia; Piha-Paul, Sarina; Akhmedzhanov, Fechukwu; Yilmaz, Bulent; McQuinn, Lacey; Brink, Amanda L; Gong, Jing; Leung, Cheuk Hong; Lin, Heather; Hong, David S; Pant, Shubham; Carter, Brett; Jazaeri, Amir; Gershenson, David; Sood, Anil K; Coleman, Robert L; Shah, Jatin; Meric-Bernstam, Funda; Naing, Aung.
Afiliação
  • Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: swestin@mdanderson.org.
  • Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsimberidou A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Akhmedzhanov F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McQuinn L; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Brink AL; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gong J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Leung CH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carter B; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jazaeri A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gershenson D; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Coleman RL; US Oncology Research, The Woodlands, TX, USA.
  • Shah J; Karyopharm Therapeutics, Inc, Newton, MA, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gynecol Oncol ; 168: 76-82, 2023 01.
Article em En | MEDLINE | ID: mdl-36423446

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Segunda Neoplasia Primária Tipo de estudo: Clinical_trials Limite: Female / Humans / Male Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Segunda Neoplasia Primária Tipo de estudo: Clinical_trials Limite: Female / Humans / Male Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article